nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—SLC10A1—Progesterone—uterine cancer	0.617	0.899	CbGbCtD
Bumetanide—PTGS2—Etoposide—uterine cancer	0.0689	0.1	CbGbCtD
Bumetanide—CFTR—semen—uterine cancer	0.0194	0.136	CbGeAlD
Bumetanide—CFTR—exocrine gland—uterine cancer	0.00821	0.0574	CbGeAlD
Bumetanide—SLC12A2—exocrine gland—uterine cancer	0.00722	0.0504	CbGeAlD
Bumetanide—Hypochloraemia—Epirubicin—uterine cancer	0.00505	0.0357	CcSEcCtD
Bumetanide—Hypochloraemia—Doxorubicin—uterine cancer	0.00467	0.033	CcSEcCtD
Bumetanide—SLC12A4—uterine cervix—uterine cancer	0.00451	0.0315	CbGeAlD
Bumetanide—Hyperventilation—Progesterone—uterine cancer	0.00396	0.028	CcSEcCtD
Bumetanide—SLC12A4—mammalian vulva—uterine cancer	0.00395	0.0276	CbGeAlD
Bumetanide—CA5A—female reproductive system—uterine cancer	0.00393	0.0275	CbGeAlD
Bumetanide—SLC12A4—uterus—uterine cancer	0.00376	0.0263	CbGeAlD
Bumetanide—Cholestasis—Progesterone—uterine cancer	0.00359	0.0253	CcSEcCtD
Bumetanide—CFTR—epithelium—uterine cancer	0.00357	0.025	CbGeAlD
Bumetanide—SLC12A4—female reproductive system—uterine cancer	0.00338	0.0236	CbGeAlD
Bumetanide—CFTR—renal system—uterine cancer	0.00331	0.0232	CbGeAlD
Bumetanide—CA7—renal system—uterine cancer	0.00326	0.0228	CbGeAlD
Bumetanide—SLC12A2—epithelium—uterine cancer	0.00314	0.0219	CbGeAlD
Bumetanide—SLC12A4—female gonad—uterine cancer	0.00308	0.0215	CbGeAlD
Bumetanide—Glycosuria—Medroxyprogesterone Acetate—uterine cancer	0.00305	0.0215	CcSEcCtD
Bumetanide—SLC12A2—decidua—uterine cancer	0.00297	0.0207	CbGeAlD
Bumetanide—Blood disorder—Medroxyprogesterone Acetate—uterine cancer	0.00296	0.0209	CcSEcCtD
Bumetanide—SLC12A2—renal system—uterine cancer	0.00291	0.0203	CbGeAlD
Bumetanide—SLC12A2—endometrium—uterine cancer	0.00281	0.0197	CbGeAlD
Bumetanide—Musculoskeletal pain—Progesterone—uterine cancer	0.00276	0.0195	CcSEcCtD
Bumetanide—SLC10A1—renal system—uterine cancer	0.00275	0.0192	CbGeAlD
Bumetanide—Hepatocellular injury—Progesterone—uterine cancer	0.00273	0.0192	CcSEcCtD
Bumetanide—SLC12A2—mammalian vulva—uterine cancer	0.00272	0.019	CbGeAlD
Bumetanide—CFTR—female reproductive system—uterine cancer	0.00265	0.0186	CbGeAlD
Bumetanide—SLC12A1—epithelium—uterine cancer	0.00263	0.0184	CbGeAlD
Bumetanide—SLC22A11—renal system—uterine cancer	0.00251	0.0176	CbGeAlD
Bumetanide—Musculoskeletal pain—Medroxyprogesterone Acetate—uterine cancer	0.0025	0.0176	CcSEcCtD
Bumetanide—Hepatocellular injury—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.0174	CcSEcCtD
Bumetanide—SLC22A7—renal system—uterine cancer	0.00245	0.0171	CbGeAlD
Bumetanide—SLC12A1—renal system—uterine cancer	0.00244	0.0171	CbGeAlD
Bumetanide—CFTR—female gonad—uterine cancer	0.00242	0.0169	CbGeAlD
Bumetanide—SLC12A2—female reproductive system—uterine cancer	0.00233	0.0163	CbGeAlD
Bumetanide—CA9—female reproductive system—uterine cancer	0.0023	0.016	CbGeAlD
Bumetanide—PTGS2—artery—uterine cancer	0.00229	0.016	CbGeAlD
Bumetanide—SLC10A1—female reproductive system—uterine cancer	0.0022	0.0154	CbGeAlD
Bumetanide—SLC12A2—female gonad—uterine cancer	0.00212	0.0148	CbGeAlD
Bumetanide—CA12—renal system—uterine cancer	0.00212	0.0148	CbGeAlD
Bumetanide—SLC12A2—vagina—uterine cancer	0.00211	0.0147	CbGeAlD
Bumetanide—SLC22A11—female reproductive system—uterine cancer	0.00201	0.0141	CbGeAlD
Bumetanide—SLC12A4—lymph node—uterine cancer	0.00198	0.0138	CbGeAlD
Bumetanide—Cramp muscle—Progesterone—uterine cancer	0.00178	0.0126	CcSEcCtD
Bumetanide—CA5B—mammalian vulva—uterine cancer	0.00178	0.0124	CbGeAlD
Bumetanide—CA12—female reproductive system—uterine cancer	0.0017	0.0119	CbGeAlD
Bumetanide—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.0119	CcSEcCtD
Bumetanide—Abdominal discomfort—Progesterone—uterine cancer	0.00164	0.0116	CcSEcCtD
Bumetanide—Hypokalaemia—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.0115	CcSEcCtD
Bumetanide—Cramp muscle—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.0114	CcSEcCtD
Bumetanide—Hyperglycaemia—Progesterone—uterine cancer	0.00154	0.0109	CcSEcCtD
Bumetanide—CA5B—female reproductive system—uterine cancer	0.00152	0.0106	CbGeAlD
Bumetanide—Hyperuricaemia—Etoposide—uterine cancer	0.0015	0.0106	CcSEcCtD
Bumetanide—Abdominal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.0105	CcSEcCtD
Bumetanide—SLCO1A2—renal system—uterine cancer	0.00148	0.0104	CbGeAlD
Bumetanide—Blood uric acid increased—Etoposide—uterine cancer	0.00142	0.01	CcSEcCtD
Bumetanide—SLC22A8—renal system—uterine cancer	0.00142	0.0099	CbGeAlD
Bumetanide—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.0014	0.00987	CcSEcCtD
Bumetanide—CA5B—vagina—uterine cancer	0.00138	0.00963	CbGeAlD
Bumetanide—SLC12A2—lymph node—uterine cancer	0.00136	0.00953	CbGeAlD
Bumetanide—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00935	CcSEcCtD
Bumetanide—CA4—renal system—uterine cancer	0.00131	0.00918	CbGeAlD
Bumetanide—Erythema multiforme—Progesterone—uterine cancer	0.00129	0.00914	CcSEcCtD
Bumetanide—Serum creatinine increased—Epirubicin—uterine cancer	0.00127	0.00897	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.00126	0.00889	CcSEcCtD
Bumetanide—Serum creatinine increased—Doxorubicin—uterine cancer	0.00118	0.0083	CcSEcCtD
Bumetanide—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00828	CcSEcCtD
Bumetanide—Muscle spasms—Progesterone—uterine cancer	0.00115	0.00809	CcSEcCtD
Bumetanide—Hyperventilation—Epirubicin—uterine cancer	0.00114	0.00802	CcSEcCtD
Bumetanide—PTGS2—myometrium—uterine cancer	0.0011	0.00772	CbGeAlD
Bumetanide—Vertigo—Progesterone—uterine cancer	0.00107	0.00756	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.00107	0.00754	CcSEcCtD
Bumetanide—CA4—female reproductive system—uterine cancer	0.00105	0.00735	CbGeAlD
Bumetanide—Hyperventilation—Doxorubicin—uterine cancer	0.00105	0.00742	CcSEcCtD
Bumetanide—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00733	CcSEcCtD
Bumetanide—Arthralgia—Progesterone—uterine cancer	0.00101	0.00716	CcSEcCtD
Bumetanide—Chest pain—Progesterone—uterine cancer	0.00101	0.00716	CcSEcCtD
Bumetanide—Dry mouth—Progesterone—uterine cancer	0.000992	0.007	CcSEcCtD
Bumetanide—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00097	0.00685	CcSEcCtD
Bumetanide—Glycosuria—Epirubicin—uterine cancer	0.000965	0.00681	CcSEcCtD
Bumetanide—CA4—female gonad—uterine cancer	0.000957	0.00669	CbGeAlD
Bumetanide—Hyperhidrosis—Progesterone—uterine cancer	0.00094	0.00664	CcSEcCtD
Bumetanide—Blood disorder—Epirubicin—uterine cancer	0.000936	0.00661	CcSEcCtD
Bumetanide—Liver injury—Epirubicin—uterine cancer	0.000929	0.00656	CcSEcCtD
Bumetanide—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000919	0.00649	CcSEcCtD
Bumetanide—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000919	0.00649	CcSEcCtD
Bumetanide—Erythema multiforme—Dactinomycin—uterine cancer	0.000915	0.00646	CcSEcCtD
Bumetanide—Cramp muscle—Etoposide—uterine cancer	0.000911	0.00643	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000911	0.00643	CcSEcCtD
Bumetanide—Hypotension—Progesterone—uterine cancer	0.000909	0.00642	CcSEcCtD
Bumetanide—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000899	0.00635	CcSEcCtD
Bumetanide—Glycosuria—Doxorubicin—uterine cancer	0.000893	0.0063	CcSEcCtD
Bumetanide—CA5B—lymph node—uterine cancer	0.000891	0.00623	CbGeAlD
Bumetanide—PTGS2—epithelium—uterine cancer	0.000867	0.00606	CbGeAlD
Bumetanide—Blood disorder—Doxorubicin—uterine cancer	0.000866	0.00611	CcSEcCtD
Bumetanide—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000863	0.00609	CcSEcCtD
Bumetanide—Liver injury—Doxorubicin—uterine cancer	0.000859	0.00607	CcSEcCtD
Bumetanide—PTGS2—uterine cervix—uterine cancer	0.000859	0.00601	CbGeAlD
Bumetanide—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000852	0.00601	CcSEcCtD
Bumetanide—Hyperuricaemia—Epirubicin—uterine cancer	0.000842	0.00595	CcSEcCtD
Bumetanide—Fatigue—Progesterone—uterine cancer	0.000838	0.00592	CcSEcCtD
Bumetanide—PTGS2—smooth muscle tissue—uterine cancer	0.000835	0.00584	CbGeAlD
Bumetanide—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000823	0.00581	CcSEcCtD
Bumetanide—PTGS2—renal system—uterine cancer	0.000804	0.00562	CbGeAlD
Bumetanide—Blood uric acid increased—Epirubicin—uterine cancer	0.000796	0.00562	CcSEcCtD
Bumetanide—Gastrointestinal pain—Progesterone—uterine cancer	0.000795	0.00561	CcSEcCtD
Bumetanide—Musculoskeletal pain—Epirubicin—uterine cancer	0.000791	0.00558	CcSEcCtD
Bumetanide—Hepatocellular injury—Epirubicin—uterine cancer	0.000782	0.00552	CcSEcCtD
Bumetanide—Hyperuricaemia—Doxorubicin—uterine cancer	0.000779	0.0055	CcSEcCtD
Bumetanide—PTGS2—endometrium—uterine cancer	0.000777	0.00543	CbGeAlD
Bumetanide—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000773	0.00546	CcSEcCtD
Bumetanide—Urticaria—Progesterone—uterine cancer	0.000772	0.00545	CcSEcCtD
Bumetanide—Abdominal pain—Progesterone—uterine cancer	0.000769	0.00543	CcSEcCtD
Bumetanide—Renal failure—Etoposide—uterine cancer	0.000767	0.00541	CcSEcCtD
Bumetanide—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00076	0.00536	CcSEcCtD
Bumetanide—Leukopenia—Dactinomycin—uterine cancer	0.000754	0.00532	CcSEcCtD
Bumetanide—Blood uric acid increased—Doxorubicin—uterine cancer	0.000736	0.0052	CcSEcCtD
Bumetanide—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000732	0.00517	CcSEcCtD
Bumetanide—Hepatocellular injury—Doxorubicin—uterine cancer	0.000723	0.00511	CcSEcCtD
Bumetanide—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00072	0.00509	CcSEcCtD
Bumetanide—PTGS2—uterus—uterine cancer	0.000716	0.005	CbGeAlD
Bumetanide—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.0007	0.00494	CcSEcCtD
Bumetanide—Asthenia—Progesterone—uterine cancer	0.000698	0.00493	CcSEcCtD
Bumetanide—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000697	0.00492	CcSEcCtD
Bumetanide—Pruritus—Progesterone—uterine cancer	0.000688	0.00486	CcSEcCtD
Bumetanide—Thrombocytopenia—Dactinomycin—uterine cancer	0.000673	0.00475	CcSEcCtD
Bumetanide—Diarrhoea—Progesterone—uterine cancer	0.000665	0.0047	CcSEcCtD
Bumetanide—Erythema multiforme—Etoposide—uterine cancer	0.000662	0.00467	CcSEcCtD
Bumetanide—PTGS2—female reproductive system—uterine cancer	0.000644	0.0045	CbGeAlD
Bumetanide—Dizziness—Progesterone—uterine cancer	0.000643	0.00454	CcSEcCtD
Bumetanide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000632	0.00446	CcSEcCtD
Bumetanide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.0044	CcSEcCtD
Bumetanide—Vomiting—Progesterone—uterine cancer	0.000618	0.00437	CcSEcCtD
Bumetanide—CA4—lymph node—uterine cancer	0.000615	0.0043	CbGeAlD
Bumetanide—Rash—Progesterone—uterine cancer	0.000613	0.00433	CcSEcCtD
Bumetanide—Dermatitis—Progesterone—uterine cancer	0.000613	0.00432	CcSEcCtD
Bumetanide—Headache—Progesterone—uterine cancer	0.000609	0.0043	CcSEcCtD
Bumetanide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000603	0.00426	CcSEcCtD
Bumetanide—Fatigue—Dactinomycin—uterine cancer	0.000593	0.00418	CcSEcCtD
Bumetanide—Muscle spasms—Etoposide—uterine cancer	0.000586	0.00414	CcSEcCtD
Bumetanide—PTGS2—female gonad—uterine cancer	0.000586	0.00409	CbGeAlD
Bumetanide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000583	0.00411	CcSEcCtD
Bumetanide—PTGS2—vagina—uterine cancer	0.000582	0.00407	CbGeAlD
Bumetanide—Nausea—Progesterone—uterine cancer	0.000578	0.00408	CcSEcCtD
Bumetanide—Hyponatraemia—Epirubicin—uterine cancer	0.00057	0.00402	CcSEcCtD
Bumetanide—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000562	0.00397	CcSEcCtD
Bumetanide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00056	0.00396	CcSEcCtD
Bumetanide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000556	0.00392	CcSEcCtD
Bumetanide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000555	0.00392	CcSEcCtD
Bumetanide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000552	0.0039	CcSEcCtD
Bumetanide—Vertigo—Etoposide—uterine cancer	0.000548	0.00387	CcSEcCtD
Bumetanide—Leukopenia—Etoposide—uterine cancer	0.000546	0.00385	CcSEcCtD
Bumetanide—Abdominal pain—Dactinomycin—uterine cancer	0.000543	0.00384	CcSEcCtD
Bumetanide—Blood creatinine increased—Epirubicin—uterine cancer	0.000531	0.00375	CcSEcCtD
Bumetanide—Dehydration—Epirubicin—uterine cancer	0.000528	0.00372	CcSEcCtD
Bumetanide—Hyponatraemia—Doxorubicin—uterine cancer	0.000527	0.00372	CcSEcCtD
Bumetanide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000523	0.0037	CcSEcCtD
Bumetanide—Chest pain—Etoposide—uterine cancer	0.000519	0.00366	CcSEcCtD
Bumetanide—Hypokalaemia—Epirubicin—uterine cancer	0.000516	0.00365	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000511	0.00361	CcSEcCtD
Bumetanide—Asthenia—Dactinomycin—uterine cancer	0.000493	0.00348	CcSEcCtD
Bumetanide—Blood creatinine increased—Doxorubicin—uterine cancer	0.000492	0.00347	CcSEcCtD
Bumetanide—Dehydration—Doxorubicin—uterine cancer	0.000488	0.00345	CcSEcCtD
Bumetanide—Thrombocytopenia—Etoposide—uterine cancer	0.000487	0.00344	CcSEcCtD
Bumetanide—Hyperhidrosis—Etoposide—uterine cancer	0.000481	0.0034	CcSEcCtD
Bumetanide—Pancreatitis—Epirubicin—uterine cancer	0.000481	0.00339	CcSEcCtD
Bumetanide—Hypokalaemia—Doxorubicin—uterine cancer	0.000478	0.00337	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000473	0.00334	CcSEcCtD
Bumetanide—Diarrhoea—Dactinomycin—uterine cancer	0.00047	0.00332	CcSEcCtD
Bumetanide—Hypotension—Etoposide—uterine cancer	0.000465	0.00328	CcSEcCtD
Bumetanide—Pancreatitis—Doxorubicin—uterine cancer	0.000445	0.00314	CcSEcCtD
Bumetanide—Hyperglycaemia—Epirubicin—uterine cancer	0.000442	0.00312	CcSEcCtD
Bumetanide—Vomiting—Dactinomycin—uterine cancer	0.000437	0.00309	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000433	0.00306	CcSEcCtD
Bumetanide—Rash—Dactinomycin—uterine cancer	0.000433	0.00306	CcSEcCtD
Bumetanide—Renal failure—Epirubicin—uterine cancer	0.00043	0.00303	CcSEcCtD
Bumetanide—Fatigue—Etoposide—uterine cancer	0.000429	0.00303	CcSEcCtD
Bumetanide—Sweating—Epirubicin—uterine cancer	0.000419	0.00296	CcSEcCtD
Bumetanide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000409	0.00289	CcSEcCtD
Bumetanide—Nausea—Dactinomycin—uterine cancer	0.000408	0.00288	CcSEcCtD
Bumetanide—Gastrointestinal pain—Etoposide—uterine cancer	0.000407	0.00287	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000401	0.00283	CcSEcCtD
Bumetanide—Renal failure—Doxorubicin—uterine cancer	0.000398	0.00281	CcSEcCtD
Bumetanide—Urticaria—Etoposide—uterine cancer	0.000395	0.00279	CcSEcCtD
Bumetanide—Abdominal pain—Etoposide—uterine cancer	0.000393	0.00278	CcSEcCtD
Bumetanide—Sweating—Doxorubicin—uterine cancer	0.000388	0.00274	CcSEcCtD
Bumetanide—PTGS2—lymph node—uterine cancer	0.000377	0.00263	CbGeAlD
Bumetanide—Erythema multiforme—Epirubicin—uterine cancer	0.000371	0.00262	CcSEcCtD
Bumetanide—Asthenia—Etoposide—uterine cancer	0.000357	0.00252	CcSEcCtD
Bumetanide—Pruritus—Etoposide—uterine cancer	0.000352	0.00248	CcSEcCtD
Bumetanide—Erythema multiforme—Doxorubicin—uterine cancer	0.000343	0.00242	CcSEcCtD
Bumetanide—Diarrhoea—Etoposide—uterine cancer	0.00034	0.0024	CcSEcCtD
Bumetanide—Dizziness—Etoposide—uterine cancer	0.000329	0.00232	CcSEcCtD
Bumetanide—Muscle spasms—Epirubicin—uterine cancer	0.000328	0.00232	CcSEcCtD
Bumetanide—Vomiting—Etoposide—uterine cancer	0.000316	0.00223	CcSEcCtD
Bumetanide—Rash—Etoposide—uterine cancer	0.000314	0.00221	CcSEcCtD
Bumetanide—Dermatitis—Etoposide—uterine cancer	0.000313	0.00221	CcSEcCtD
Bumetanide—Headache—Etoposide—uterine cancer	0.000312	0.0022	CcSEcCtD
Bumetanide—Vertigo—Epirubicin—uterine cancer	0.000307	0.00217	CcSEcCtD
Bumetanide—Leukopenia—Epirubicin—uterine cancer	0.000306	0.00216	CcSEcCtD
Bumetanide—Muscle spasms—Doxorubicin—uterine cancer	0.000304	0.00215	CcSEcCtD
Bumetanide—Nausea—Etoposide—uterine cancer	0.000295	0.00209	CcSEcCtD
Bumetanide—Arthralgia—Epirubicin—uterine cancer	0.000291	0.00205	CcSEcCtD
Bumetanide—Chest pain—Epirubicin—uterine cancer	0.000291	0.00205	CcSEcCtD
Bumetanide—Dry mouth—Epirubicin—uterine cancer	0.000284	0.00201	CcSEcCtD
Bumetanide—Vertigo—Doxorubicin—uterine cancer	0.000284	0.00201	CcSEcCtD
Bumetanide—Leukopenia—Doxorubicin—uterine cancer	0.000283	0.002	CcSEcCtD
Bumetanide—Thrombocytopenia—Epirubicin—uterine cancer	0.000273	0.00193	CcSEcCtD
Bumetanide—Hyperhidrosis—Epirubicin—uterine cancer	0.00027	0.0019	CcSEcCtD
Bumetanide—Arthralgia—Doxorubicin—uterine cancer	0.000269	0.0019	CcSEcCtD
Bumetanide—Chest pain—Doxorubicin—uterine cancer	0.000269	0.0019	CcSEcCtD
Bumetanide—Dry mouth—Doxorubicin—uterine cancer	0.000263	0.00186	CcSEcCtD
Bumetanide—Hypotension—Epirubicin—uterine cancer	0.000261	0.00184	CcSEcCtD
Bumetanide—Thrombocytopenia—Doxorubicin—uterine cancer	0.000253	0.00178	CcSEcCtD
Bumetanide—Hyperhidrosis—Doxorubicin—uterine cancer	0.000249	0.00176	CcSEcCtD
Bumetanide—Hypotension—Doxorubicin—uterine cancer	0.000241	0.0017	CcSEcCtD
Bumetanide—Fatigue—Epirubicin—uterine cancer	0.00024	0.0017	CcSEcCtD
Bumetanide—Gastrointestinal pain—Epirubicin—uterine cancer	0.000228	0.00161	CcSEcCtD
Bumetanide—Fatigue—Doxorubicin—uterine cancer	0.000222	0.00157	CcSEcCtD
Bumetanide—Urticaria—Epirubicin—uterine cancer	0.000221	0.00156	CcSEcCtD
Bumetanide—Abdominal pain—Epirubicin—uterine cancer	0.00022	0.00156	CcSEcCtD
Bumetanide—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000211	0.00149	CcSEcCtD
Bumetanide—Urticaria—Doxorubicin—uterine cancer	0.000205	0.00145	CcSEcCtD
Bumetanide—Abdominal pain—Doxorubicin—uterine cancer	0.000204	0.00144	CcSEcCtD
Bumetanide—Asthenia—Epirubicin—uterine cancer	0.0002	0.00141	CcSEcCtD
Bumetanide—Pruritus—Epirubicin—uterine cancer	0.000197	0.00139	CcSEcCtD
Bumetanide—Diarrhoea—Epirubicin—uterine cancer	0.000191	0.00135	CcSEcCtD
Bumetanide—Asthenia—Doxorubicin—uterine cancer	0.000185	0.00131	CcSEcCtD
Bumetanide—Dizziness—Epirubicin—uterine cancer	0.000184	0.0013	CcSEcCtD
Bumetanide—Pruritus—Doxorubicin—uterine cancer	0.000183	0.00129	CcSEcCtD
Bumetanide—Vomiting—Epirubicin—uterine cancer	0.000177	0.00125	CcSEcCtD
Bumetanide—Diarrhoea—Doxorubicin—uterine cancer	0.000177	0.00125	CcSEcCtD
Bumetanide—Rash—Epirubicin—uterine cancer	0.000176	0.00124	CcSEcCtD
Bumetanide—Dermatitis—Epirubicin—uterine cancer	0.000176	0.00124	CcSEcCtD
Bumetanide—Headache—Epirubicin—uterine cancer	0.000175	0.00123	CcSEcCtD
Bumetanide—Dizziness—Doxorubicin—uterine cancer	0.000171	0.0012	CcSEcCtD
Bumetanide—Nausea—Epirubicin—uterine cancer	0.000166	0.00117	CcSEcCtD
Bumetanide—Vomiting—Doxorubicin—uterine cancer	0.000164	0.00116	CcSEcCtD
Bumetanide—Rash—Doxorubicin—uterine cancer	0.000163	0.00115	CcSEcCtD
Bumetanide—Dermatitis—Doxorubicin—uterine cancer	0.000163	0.00115	CcSEcCtD
Bumetanide—Headache—Doxorubicin—uterine cancer	0.000162	0.00114	CcSEcCtD
Bumetanide—Nausea—Doxorubicin—uterine cancer	0.000153	0.00108	CcSEcCtD
Bumetanide—SLC10A1—Metabolism—SRD5A2—uterine cancer	0.000109	0.00369	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—NDUFB11—uterine cancer	0.000109	0.00369	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000106	0.00359	CbGpPWpGaD
Bumetanide—CA4—Metabolism—NDUFB11—uterine cancer	0.000104	0.00352	CbGpPWpGaD
Bumetanide—CA4—Metabolism—SRD5A2—uterine cancer	0.000104	0.00352	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000103	0.00348	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKR1B1—uterine cancer	0.000102	0.00345	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKR1B1—uterine cancer	0.000102	0.00345	CbGpPWpGaD
Bumetanide—CA7—Metabolism—STAR—uterine cancer	0.000102	0.00345	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—STAR—uterine cancer	0.000102	0.00345	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.0001	0.00339	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CDKN2B—uterine cancer	9.98e-05	0.00337	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKR1B1—uterine cancer	9.45e-05	0.00319	CbGpPWpGaD
Bumetanide—CA12—Metabolism—STAR—uterine cancer	9.45e-05	0.00319	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—ABCC9—uterine cancer	9.35e-05	0.00316	CbGpPWpGaD
Bumetanide—CA14—Metabolism—POLD1—uterine cancer	8.8e-05	0.00297	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	8.73e-05	0.00295	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	8.73e-05	0.00295	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—POLD1—uterine cancer	8.58e-05	0.0029	CbGpPWpGaD
Bumetanide—CA9—Metabolism—NDUFB11—uterine cancer	8.43e-05	0.00285	CbGpPWpGaD
Bumetanide—CA9—Metabolism—SRD5A2—uterine cancer	8.43e-05	0.00285	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	8.3e-05	0.0028	CbGpPWpGaD
Bumetanide—CA14—Metabolism—AKR1C1—uterine cancer	8.23e-05	0.00278	CbGpPWpGaD
Bumetanide—CA9—HIF-1-alpha transcription factor network—AKT1—uterine cancer	8.13e-05	0.00275	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—AKR1C1—uterine cancer	8.02e-05	0.00271	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—POLD1—uterine cancer	8.01e-05	0.0027	CbGpPWpGaD
Bumetanide—CA7—Metabolism—POLD1—uterine cancer	8.01e-05	0.0027	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—STAR—uterine cancer	7.9e-05	0.00267	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKR1B1—uterine cancer	7.9e-05	0.00267	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	7.88e-05	0.00266	CbGpPWpGaD
Bumetanide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	7.84e-05	0.00265	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.81e-05	0.00264	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.8e-05	0.00264	CbGpPWpGaD
Bumetanide—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	7.77e-05	0.00262	CbGpPWpGaD
Bumetanide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	7.55e-05	0.00255	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKR1B1—uterine cancer	7.54e-05	0.00255	CbGpPWpGaD
Bumetanide—CA4—Metabolism—STAR—uterine cancer	7.54e-05	0.00255	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKR1C1—uterine cancer	7.49e-05	0.00253	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKR1C1—uterine cancer	7.49e-05	0.00253	CbGpPWpGaD
Bumetanide—CA12—Metabolism—POLD1—uterine cancer	7.42e-05	0.00251	CbGpPWpGaD
Bumetanide—CA14—Metabolism—RRM2—uterine cancer	7.34e-05	0.00248	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.29e-05	0.00246	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—RRM2—uterine cancer	7.15e-05	0.00241	CbGpPWpGaD
Bumetanide—CA14—Metabolism—DCN—uterine cancer	7.12e-05	0.00241	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—DCN—uterine cancer	6.94e-05	0.00234	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKR1C1—uterine cancer	6.94e-05	0.00234	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	6.92e-05	0.00234	CbGpPWpGaD
Bumetanide—CA14—Metabolism—CYP11A1—uterine cancer	6.71e-05	0.00227	CbGpPWpGaD
Bumetanide—CA7—Metabolism—RRM2—uterine cancer	6.68e-05	0.00225	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—RRM2—uterine cancer	6.68e-05	0.00225	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	6.6e-05	0.00223	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	6.56e-05	0.00221	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—CYP11A1—uterine cancer	6.54e-05	0.00221	CbGpPWpGaD
Bumetanide—CA7—Metabolism—DCN—uterine cancer	6.48e-05	0.00219	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—DCN—uterine cancer	6.48e-05	0.00219	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	6.48e-05	0.00219	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.41e-05	0.00216	CbGpPWpGaD
Bumetanide—CA14—Metabolism—AKR1C3—uterine cancer	6.34e-05	0.00214	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—POLD1—uterine cancer	6.2e-05	0.00209	CbGpPWpGaD
Bumetanide—CA12—Metabolism—RRM2—uterine cancer	6.19e-05	0.00209	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—AKR1C3—uterine cancer	6.18e-05	0.00209	CbGpPWpGaD
Bumetanide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	6.16e-05	0.00208	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	6.12e-05	0.00207	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CYP11A1—uterine cancer	6.11e-05	0.00206	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CYP11A1—uterine cancer	6.11e-05	0.00206	CbGpPWpGaD
Bumetanide—CA9—Metabolism—STAR—uterine cancer	6.09e-05	0.00206	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKR1B1—uterine cancer	6.09e-05	0.00206	CbGpPWpGaD
Bumetanide—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	6.08e-05	0.00205	CbGpPWpGaD
Bumetanide—CA12—Metabolism—DCN—uterine cancer	6e-05	0.00203	CbGpPWpGaD
Bumetanide—CA4—Metabolism—POLD1—uterine cancer	5.92e-05	0.002	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKR1C1—uterine cancer	5.8e-05	0.00196	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKR1C3—uterine cancer	5.77e-05	0.00195	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKR1C3—uterine cancer	5.77e-05	0.00195	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CDKN2A—uterine cancer	5.71e-05	0.00193	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CYP11A1—uterine cancer	5.66e-05	0.00191	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	5.57e-05	0.00188	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	5.56e-05	0.00188	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKR1C1—uterine cancer	5.53e-05	0.00187	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	5.5e-05	0.00186	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—SRD5A2—uterine cancer	5.38e-05	0.00182	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—NDUFB11—uterine cancer	5.38e-05	0.00182	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKR1C3—uterine cancer	5.34e-05	0.0018	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.27e-05	0.00178	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.27e-05	0.00178	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	5.22e-05	0.00176	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CXCL8—uterine cancer	5.18e-05	0.00175	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—RRM2—uterine cancer	5.17e-05	0.00175	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CDKN1B—uterine cancer	5.05e-05	0.00171	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—DCN—uterine cancer	5.02e-05	0.00169	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	4.98e-05	0.00168	CbGpPWpGaD
Bumetanide—CA14—Metabolism—STK11—uterine cancer	4.94e-05	0.00167	CbGpPWpGaD
Bumetanide—CA14—Metabolism—CYP19A1—uterine cancer	4.94e-05	0.00167	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.93e-05	0.00167	CbGpPWpGaD
Bumetanide—CA4—Metabolism—RRM2—uterine cancer	4.93e-05	0.00167	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	4.87e-05	0.00164	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—STK11—uterine cancer	4.81e-05	0.00162	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—CYP19A1—uterine cancer	4.81e-05	0.00162	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	4.81e-05	0.00162	CbGpPWpGaD
Bumetanide—CA4—Metabolism—DCN—uterine cancer	4.79e-05	0.00162	CbGpPWpGaD
Bumetanide—CA9—Metabolism—POLD1—uterine cancer	4.78e-05	0.00161	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	4.74e-05	0.0016	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CYP11A1—uterine cancer	4.73e-05	0.0016	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CYP11A1—uterine cancer	4.51e-05	0.00152	CbGpPWpGaD
Bumetanide—CA7—Metabolism—STK11—uterine cancer	4.49e-05	0.00152	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—STK11—uterine cancer	4.49e-05	0.00152	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CYP19A1—uterine cancer	4.49e-05	0.00152	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CYP19A1—uterine cancer	4.49e-05	0.00152	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKR1C1—uterine cancer	4.47e-05	0.00151	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKR1C3—uterine cancer	4.47e-05	0.00151	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—EP300—uterine cancer	4.44e-05	0.0015	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	4.28e-05	0.00144	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKR1C3—uterine cancer	4.26e-05	0.00144	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—VEGFA—uterine cancer	4.2e-05	0.00142	CbGpPWpGaD
Bumetanide—CA12—Metabolism—STK11—uterine cancer	4.16e-05	0.00141	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CYP19A1—uterine cancer	4.16e-05	0.00141	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	4e-05	0.00135	CbGpPWpGaD
Bumetanide—CA9—Metabolism—RRM2—uterine cancer	3.99e-05	0.00135	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKR1B1—uterine cancer	3.89e-05	0.00131	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—STAR—uterine cancer	3.89e-05	0.00131	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.87e-05	0.00131	CbGpPWpGaD
Bumetanide—CA9—Metabolism—DCN—uterine cancer	3.87e-05	0.00131	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.84e-05	0.0013	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	3.8e-05	0.00128	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	3.71e-05	0.00125	CbGpPWpGaD
Bumetanide—CA14—Metabolism—MTHFR—uterine cancer	3.71e-05	0.00125	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	3.71e-05	0.00125	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CYP11A1—uterine cancer	3.65e-05	0.00123	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—MTHFR—uterine cancer	3.62e-05	0.00122	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—STK11—uterine cancer	3.48e-05	0.00117	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CYP19A1—uterine cancer	3.48e-05	0.00117	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	3.44e-05	0.00116	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKR1C3—uterine cancer	3.44e-05	0.00116	CbGpPWpGaD
Bumetanide—CA7—Metabolism—MTHFR—uterine cancer	3.38e-05	0.00114	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—MTHFR—uterine cancer	3.38e-05	0.00114	CbGpPWpGaD
Bumetanide—CA4—Metabolism—STK11—uterine cancer	3.32e-05	0.00112	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CYP19A1—uterine cancer	3.32e-05	0.00112	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.27e-05	0.0011	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NDUFB11—uterine cancer	3.25e-05	0.0011	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—SRD5A2—uterine cancer	3.25e-05	0.0011	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—TP53—uterine cancer	3.18e-05	0.00107	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.16e-05	0.00107	CbGpPWpGaD
Bumetanide—CA12—Metabolism—MTHFR—uterine cancer	3.13e-05	0.00106	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.11e-05	0.00105	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—POLD1—uterine cancer	3.05e-05	0.00103	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKR1B10—uterine cancer	3.02e-05	0.00102	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.98e-05	0.00101	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	2.93e-05	0.000988	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKR1C1—uterine cancer	2.85e-05	0.000964	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.73e-05	0.00092	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CYP19A1—uterine cancer	2.68e-05	0.000906	CbGpPWpGaD
Bumetanide—CA9—Metabolism—STK11—uterine cancer	2.68e-05	0.000906	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—MTHFR—uterine cancer	2.61e-05	0.000883	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—RRM2—uterine cancer	2.54e-05	0.000859	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.52e-05	0.000852	CbGpPWpGaD
Bumetanide—PTGS2—Disease—RNF43—uterine cancer	2.5e-05	0.000844	CbGpPWpGaD
Bumetanide—CA4—Metabolism—MTHFR—uterine cancer	2.49e-05	0.000842	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—DCN—uterine cancer	2.47e-05	0.000834	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.38e-05	0.000805	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—STAR—uterine cancer	2.35e-05	0.000793	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKR1B1—uterine cancer	2.35e-05	0.000793	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TP53—uterine cancer	2.33e-05	0.000787	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CYP11A1—uterine cancer	2.33e-05	0.000786	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.32e-05	0.000785	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.32e-05	0.000784	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.3e-05	0.000778	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.22e-05	0.000748	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKR1C3—uterine cancer	2.2e-05	0.000742	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.1e-05	0.000709	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PTEN—uterine cancer	2.06e-05	0.000697	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKR1C1—uterine cancer	2.06e-05	0.000695	CbGpPWpGaD
Bumetanide—CA9—Metabolism—MTHFR—uterine cancer	2.02e-05	0.000681	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PTEN—uterine cancer	2.01e-05	0.000679	CbGpPWpGaD
Bumetanide—CA14—Metabolism—EP300—uterine cancer	1.97e-05	0.000665	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—EP300—uterine cancer	1.92e-05	0.000648	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PTEN—uterine cancer	1.88e-05	0.000634	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PTEN—uterine cancer	1.88e-05	0.000634	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—POLD1—uterine cancer	1.84e-05	0.000622	CbGpPWpGaD
Bumetanide—CA7—Metabolism—EP300—uterine cancer	1.79e-05	0.000605	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—EP300—uterine cancer	1.79e-05	0.000605	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.78e-05	0.000603	CbGpPWpGaD
Bumetanide—PTGS2—Disease—DCN—uterine cancer	1.78e-05	0.000601	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PTEN—uterine cancer	1.74e-05	0.000587	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKR1C1—uterine cancer	1.72e-05	0.000582	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—STK11—uterine cancer	1.71e-05	0.000578	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CYP19A1—uterine cancer	1.71e-05	0.000578	CbGpPWpGaD
Bumetanide—CA12—Metabolism—EP300—uterine cancer	1.66e-05	0.00056	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.64e-05	0.000554	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.61e-05	0.000543	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.59e-05	0.000536	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKR1C3—uterine cancer	1.58e-05	0.000535	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HMGA1—uterine cancer	1.54e-05	0.000521	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—RRM2—uterine cancer	1.54e-05	0.000519	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.53e-05	0.000517	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—DCN—uterine cancer	1.49e-05	0.000504	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PIK3CA—uterine cancer	1.46e-05	0.000492	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PTEN—uterine cancer	1.45e-05	0.000491	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PIK3CA—uterine cancer	1.42e-05	0.000479	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FBXW7—uterine cancer	1.41e-05	0.000477	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CYP11A1—uterine cancer	1.41e-05	0.000474	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PTEN—uterine cancer	1.39e-05	0.000469	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—EP300—uterine cancer	1.39e-05	0.000468	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.34e-05	0.000452	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKR1C3—uterine cancer	1.33e-05	0.000448	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PIK3CA—uterine cancer	1.32e-05	0.000447	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PIK3CA—uterine cancer	1.32e-05	0.000447	CbGpPWpGaD
Bumetanide—CA4—Metabolism—EP300—uterine cancer	1.32e-05	0.000447	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—MTHFR—uterine cancer	1.29e-05	0.000434	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PIK3CA—uterine cancer	1.23e-05	0.000414	CbGpPWpGaD
Bumetanide—CA14—Metabolism—AKT1—uterine cancer	1.19e-05	0.000402	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—AKT1—uterine cancer	1.16e-05	0.000391	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.13e-05	0.000383	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PTEN—uterine cancer	1.12e-05	0.000379	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CDKN2B—uterine cancer	1.11e-05	0.000374	CbGpPWpGaD
Bumetanide—CA7—Metabolism—AKT1—uterine cancer	1.08e-05	0.000365	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—AKT1—uterine cancer	1.08e-05	0.000365	CbGpPWpGaD
Bumetanide—CA9—Metabolism—EP300—uterine cancer	1.07e-05	0.000361	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—STK11—uterine cancer	1.03e-05	0.000349	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CYP19A1—uterine cancer	1.03e-05	0.000349	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PIK3CA—uterine cancer	1.03e-05	0.000346	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SMAD3—uterine cancer	1.01e-05	0.000341	CbGpPWpGaD
Bumetanide—CA12—Metabolism—AKT1—uterine cancer	1e-05	0.000339	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PIK3CA—uterine cancer	9.79e-06	0.000331	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.7e-06	0.000328	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FGFR2—uterine cancer	9.64e-06	0.000325	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MTHFR—uterine cancer	9.28e-06	0.000313	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.25e-06	0.000312	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—AKT1—uterine cancer	8.38e-06	0.000283	CbGpPWpGaD
Bumetanide—CA4—Metabolism—AKT1—uterine cancer	8e-06	0.00027	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PIK3CA—uterine cancer	7.91e-06	0.000267	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—MTHFR—uterine cancer	7.77e-06	0.000262	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PTEN—uterine cancer	7.16e-06	0.000242	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.85e-06	0.000231	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—EP300—uterine cancer	6.82e-06	0.00023	CbGpPWpGaD
Bumetanide—CA9—Metabolism—AKT1—uterine cancer	6.46e-06	0.000218	CbGpPWpGaD
Bumetanide—PTGS2—Disease—ERBB2—uterine cancer	6.05e-06	0.000204	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CDKN1B—uterine cancer	5.6e-06	0.000189	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CTNNB1—uterine cancer	5.29e-06	0.000179	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PTEN—uterine cancer	5.16e-06	0.000174	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PIK3CA—uterine cancer	5.05e-06	0.00017	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EP300—uterine cancer	4.92e-06	0.000166	CbGpPWpGaD
Bumetanide—PTGS2—Disease—NRAS—uterine cancer	4.6e-06	0.000155	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PTEN—uterine cancer	4.32e-06	0.000146	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—AKT1—uterine cancer	4.12e-06	0.000139	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—EP300—uterine cancer	4.12e-06	0.000139	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KRAS—uterine cancer	3.96e-06	0.000134	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PIK3CA—uterine cancer	3.64e-06	0.000123	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HRAS—uterine cancer	3.37e-06	0.000114	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PIK3CA—uterine cancer	3.05e-06	0.000103	CbGpPWpGaD
Bumetanide—PTGS2—Disease—AKT1—uterine cancer	2.97e-06	0.0001	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—AKT1—uterine cancer	2.49e-06	8.41e-05	CbGpPWpGaD
